tert-butyl 4-(5-azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-benzoate | 324789-00-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-(5-azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-benzoate
• 英文别名: tert-butyl 4-[(5R)-5-(azidomethyl)-2-oxo-1,3-oxazolidin-3-yl]-2-fluorobenzoate
• CAS: 324789-00-6
• 化学式: C₁₅H₁₇FN₄O₄
• 分子量: 336.323
• InChiKey: WJYBZHPWAQYWSF-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(5-azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-benzoate 在 吡啶 、 水 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-(S)-acetamidomethyl-3-[4'-(pentafluorophenyl)oxycarbonyl-3'-fluorophenyl]-oxazolidine-2-one
  参考文献：
  名称：

  Novel oxazolidinone–quinolone hybrid antimicrobials

  摘要：

  Antimicrobial compounds incorporating oxazolidinone and quinolone pharmacophore substructures have been synthesized and evaluated. Representative analogues 2, 5, and 6 display an improved potency versus linezolid against gram-positive and fastidious gram-negative pathogens. The compounds are also active against linezolid- and ciprofloxacin-resistant Staphylococcus aureus and Enterococcus faecium strains. The MOA for these new antimicrobials is consistent with a combination of protein synthesis and gyrase A/topoisomerase IV inhibition, with a structure-dependent degree of the contribution from each inhibitory mechanism. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.021
• 作为产物：
  描述：

  叔-丁基 4-氨基-2-氟苯甲酸 在 吡啶 、 sodium azide 、 TEA 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl 4-(5-azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-benzoate
  参考文献：
  名称：

  Novel oxazolidinone–quinolone hybrid antimicrobials

  摘要：

  Antimicrobial compounds incorporating oxazolidinone and quinolone pharmacophore substructures have been synthesized and evaluated. Representative analogues 2, 5, and 6 display an improved potency versus linezolid against gram-positive and fastidious gram-negative pathogens. The compounds are also active against linezolid- and ciprofloxacin-resistant Staphylococcus aureus and Enterococcus faecium strains. The MOA for these new antimicrobials is consistent with a combination of protein synthesis and gyrase A/topoisomerase IV inhibition, with a structure-dependent degree of the contribution from each inhibitory mechanism. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.021

文献信息

• Aryl substituted oxazolidinones with antibacterial activity
  申请人：Gravestock Barry Michael

  公开号：US20050043374A1

  公开（公告）日：2005-02-24

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, or HET is an N-linked 6-membered di-hydro-heteroaryl ring; Q is, for example, Q1 or Q2: wherein R 2 and R 3 are independently hydrogen or fluoro; T is, for example, (TAa1) or (TAa2): wherein R 4h and R 5h are independently selected, for example, from hydrogen, halo, trifluoromethyl, cyano, nitro and (1-4C)alkoxy; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  化合物的公式（I），或其药学上可接受的盐，或其体内可水解的酯，其中，例如，HET是一个N-连接的5元、完全或部分不饱和的杂环环，或者HET是一个N-连接的6元双氢杂环芳基环；Q是，例如，Q1或Q2：其中R2和R3独立地是氢或氟；T是，例如，（TAa1）或（TAa2）：其中R4h和R5h独立地从氢、卤、三氟甲基、氰、硝基和（1-4C）烷氧基中选取，可用作抗菌剂；并描述了制造它们的过程和含有它们的制药组合物。
• NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS
  申请人：Takhi Mohamed

  公开号：US20100298384A1

  公开（公告）日：2010-11-25

  The present invention relates to novel oxazolidinone compounds of formula (I) with antibacterial activity, their pharmaceutically acceptable salts, their stereoisomers, their prodrugs, pharmaceutical compositions comprising the same and to their use as therapeutic agents

  本发明涉及具有抗菌活性的新型噁唑烷酮化合物（I）及其药学上可接受的盐、立体异构体、前药、包含其的制药组合物以及将其用作治疗剂的用途。
• WO2008/143649
  申请人：——

  公开号：——

  公开（公告）日：——
• ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1446403B1

  公开（公告）日：2006-04-12
• [EN] ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY<br/>[FR] OXAZOLIDINONES SUBSTITUEES PAR UN GROUPE ARYLE PRESENTANT UNE ACTIVITE ANTIBACTERIENNE
  申请人：ASTRAZENECA AB

  公开号：WO2003035648A1

  公开（公告）日：2003-05-01

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, HET is an N-linked 5-membered, fully or partially unsaturated heterocyclic ring, or HET is an N-linked 6-membered di-hydro-heteroaryl ring; Q is, for example, Q1 or Q2: wherein R?2 and R3¿ are independently hydrogen or fluoro; T is, for example, (TAa1) or (TAa2): wherein R?4h and R5h¿ are independently selected, for example, from hydrogen, halo, trifluoromethyl, cyano, nitro and (1-4C)alkoxy; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.